Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150
Magdalena Espinoza, Maishara Muquith, Mir Lim, et al.
Gastroenterology (2023) Vol. 165, Iss. 1, pp. 286-288.e4
Closed Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
Amit G. Singal, Fasiha Kanwal, Josep M. Llovet
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 864-884
Closed Access | Times Cited: 324
MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
Anju Phoolchund, Salim I. Khakoo
Cancers (2024) Vol. 16, Iss. 2, pp. 259-259
Open Access | Times Cited: 32
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 4, pp. 310-322
Closed Access | Times Cited: 32
Advances in Immunotherapy in Hepatocellular Carcinoma
Matthew B. Bloom, S. Podder, Hien Dang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 1936-1936
Open Access | Times Cited: 2
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Anand V. Kulkarni, Harsh Vardhan Tevethia, Karan Kumar, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102179-102179
Open Access | Times Cited: 26
Translational research on drug development and biomarker discovery for hepatocellular carcinoma
Valerie Chew, Chien-Huai Chuang, Chiun Hsu
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 9
Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
Jia‐Yong Su, Kang Chen, Zhen Liu, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options
Yuming Shi, Erfan Taherifard, A.I. Saeed, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 6, pp. 5965-5983
Open Access | Times Cited: 7
Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?
Elisa Pinto, Paola Meneghel, Fabio Farinati, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 4, pp. 579-588
Open Access | Times Cited: 14
Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
Linda Y. Wu, Sarah Cappuyns, Amanda S. Loh, et al.
BJC Reports (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 5
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
Liver Cancer (2024) Vol. 13, Iss. 5, pp. 522-536
Open Access | Times Cited: 5
No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC
Francisca‐Dora Copil, Claudia Campani, Marie Lequoy, et al.
Liver International (2024) Vol. 44, Iss. 4, pp. 931-943
Closed Access | Times Cited: 4
Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?
Wiebke Werner, Maria Kuzminskaya, Isabella Lurje, et al.
Seminars in Liver Disease (2024) Vol. 44, Iss. 02, pp. 159-179
Open Access | Times Cited: 4
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Eléonora De Martin, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
Gut (2024), pp. gutjnl-332125
Closed Access | Times Cited: 3
State of CD8+ T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy
Xin Zhong, Minling Lv, Mengqing Ma, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115131-115131
Open Access | Times Cited: 7
Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
Valentina Zanuso, Angelo Pirozzi, Rita Balsano, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1689-1708
Open Access | Times Cited: 7
Treatment options for advanced hepatocellular carcinoma: the potential of biologics
Federico Rossari, Silvia Foti, Silvia Camera, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 6, pp. 455-470
Closed Access | Times Cited: 2
Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts
Michihisa Moriguchi, Seita Kataoka, Yoshito Itoh
Cancers (2024) Vol. 16, Iss. 13, pp. 2387-2387
Open Access | Times Cited: 2
Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice
Kenta Motomura, Akifumi Kuwano, Kosuke Tanaka, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4345-4345
Open Access | Times Cited: 6
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4348-4348
Open Access | Times Cited: 6
Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology
Josep M. Llovet, Mathias Heikenwälder
Gastroenterology (2023) Vol. 165, Iss. 5, pp. 1308-1310
Open Access | Times Cited: 4
The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy
Valentina Zanuso, Lorenza Rimassa, Chiara Braconi
Hepatology (2023)
Closed Access | Times Cited: 4
Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy
Darren Cowzer, Joanne F. Chou, Henry Walch, et al.
The Oncologist (2024) Vol. 29, Iss. 10, pp. 894-903
Open Access | Times Cited: 1
Successful radical surgery for lymph node metastasis in a patient with hepatocellular carcinoma following atezolizumab plus bevacizumab combination therapy: a case report and literature review
Ken Sato, Takehiro Shimizu, Akira Watanabe, et al.
Clinical Journal of Gastroenterology (2024) Vol. 17, Iss. 6, pp. 1067-1074
Closed Access | Times Cited: 1
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results
Leonardo Stella, Clémence Hollande, Yasmina Ben Merabet, et al.
Expert Opinion on Emerging Drugs (2024)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top